Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
Illumina has partnered with Boehringer Ingelheim to develop companion diagnostics for its oncology programs aimed at enhancing precision medicine for advanced cancer patients. The collaboration will fast-track therapy selection by adding companion diagnostic claims to Illumina's TruSight Oncology 500 assay. This initiative emphasizes the use of comprehensive genomic profiling to identify patients suited for novel therapies. Joydeep Goswami from Illumina expressed enthusiasm over the long-term partnership, highlighting its potential in unlocking new biomarkers critical for cancer treatment.
- Partnership with Boehringer Ingelheim focuses on companion diagnostics for oncology.
- Development of CDx claims for TruSight Oncology 500, enhancing precision medicine.
- Aims to improve patient therapy selection in advanced cancer treatments.
- None.
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
The partnership spans current and future CDx programs, with plans to add CDx claims to an in vitro diagnostic test Illumina is developing that is based on the content of TruSight™ Oncology 500 (TSO 500). The first program will co-develop a CDx for a Boehringer Ingelheim investigational medicine.
"We are delighted that Boehringer Ingelheim has chosen Illumina to be its long-term partner in the development of companion diagnostics for the treatment of cancers," said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. "Illumina continues to provide the leading distributable assay enabling comprehensive genomic profiling for both tissue and liquid biopsy and together we will unlock the potential of new biomarkers to identify patients most likely to benefit from new precision medicines."
About TruSight Oncology 500
TSO 500 is a Research Use Only comprehensive pan-cancer assay designed to identify 523 known and emerging tumor biomarkers. TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic test to the TruSight Oncology product family. This comprehensive tumor profiling assay will have similar chemistry and analytics to TSO 500. To learn more about TSO 500, click here.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the (a? – please ask Legal) global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
858.291.6421
IR@illumina.com
Media:
Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111
kbirmingham@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-boehringer-ingelheim-announce-companion-diagnostic-partnership-301456760.html
SOURCE Illumina, Inc.
FAQ
What is the partnership between Illumina and Boehringer Ingelheim about?
How will the partnership impact precision medicine in oncology?
What is TruSight Oncology 500?
What is the significance of the CDx claims in the partnership?
When was the partnership between Illumina and Boehringer Ingelheim announced?
